MINI-REVIEW

Kisspeptins (KiSS-1): Essential Players in Suppressing Tumor Metastasis

Venugopal Vinod Prabhu, Kunnathur Murugesan Sakthivel, Chandrasekharan Guruvayoorappan*

Abstract

Kisspeptins (KPs) encoded by the KiSS-1 gene are C-terminally amidated peptide products, including KP-10, KP-13, KP-14 and KP-54, which are endogenous agonists for the G-protein coupled receptor-54 (GPR54). Functional analyses have demonstrated fundamental roles of KiSS-1 in whole body homeostasis including sexual differentiation of brain, action on sex steroids and metabolic regulation of fertility essential for human puberty and maintenance of adult reproduction. In addition, intensive recent investigations have provided substantial evidence suggesting roles of Kisspeptin signalling via its receptor GPR54 in the suppression of metastasis with a variety of cancers. The present review highlights the latest studies regarding the role of Kisspeptins and the KiSS-1 gene in tumor progression and also suggests targeting the KiSS-1/GPR54 system may represent a novel therapeutic approach for cancers. Further investigations are essential to elucidate the complex pathways regulated by the Kisspeptins and how these pathways might be involved in the suppression of metastasis across a range of cancers.

Keywords: Kisspeptins - GPR54 receptor - KiSS-1 gene - metastasis - cancer

Asian Pac J Cancer Prev, 14 (11), 6215-6220

Introduction

Cancer is a class of disease characterized by out-of-control cell growth. Cancer disease is a leading cause of death and accounted for 7.6 million deaths in 2008 and could rise to 13.1 million deaths by year 2030 (WHO, 2008). The reason behind such high mortality from cancer is due to their extremely invasive behaviour which typically results in metastasis (Khan and Mukhtar, 2010).

Metastasis is an extremely complex process that remains to be a major problem in the management of cancer (Hunter et al., 2008). Metastasis is a multistep process, which includes loss of cell-cell adhesion within neoplastic epithelium, invasion of surrounding tissues, angiogenesis and dissemination of cancer cells through vascular and lymphatic vessels, ranspassing through vascular endothelium into distant sites (Hanahan and Weinberg, 2011; Sakthivel et al., 2012). Each step must be successfully completed to give rise to a metastatic tumor. Now-a-days, cancer research is focusing on the blockade of the metastatic process at its early stage.

Therefore, there is growing interest in identifying metastasis suppressor genes, which may be involved in the anti-metastatic activity. Numerous experimental studies reveals that understanding the expression and mechanism of genes and gene products that inhibits cancer metastasis could be a potential molecular target in preventing cancer deaths (Stafford et al., 2008). There are around 20 different metastasis suppressor genes which brings a valuable mechanistic insight for guiding specific therapeutic strategies for cancer including gene transfer, induction of previously suppressed gene expression, exogenous administration of gene product, drug-induced reactivation of metastasis suppressor genes and signalling pathways.

Among metastasis-suppressor genes, KiSS-1 is the only one that binds to a G-protein coupled receptor (GPR54 or AXOR12 or hOT7T175) and is believed to act late in the metastatic cascade by preventing growth of the metastatic deposit, as opposed to early metastasis suppressor genes [Non metastasis genes (Nm23, KAI1)] that suppress cell detachment and migration from the primary tumor (Bari et al., 2009; Prabhu et al., 2012). KiSS-1 (formerly known as metastin) occur naturally in human placenta which was named for its role as a suppressor sequence (SS); the letters “Ki” were appended to the prefix “SS” to form “KiSS” in homage to the location of its discovery, Hershey, Pennsylvania, home of the famous “Hershey Chocolate Kisses” (Kotani et al., 2001; Shevde et al., 2003; Iizumi et al., 2008; Smith and Theodorescu, 2009). It is well known that KiSS-1 gene involve in tumor biology and metastatic process, therefore, in this review we discuss the potential roles of the KiSS-1 gene during tumor progression and how it could be used as a potential molecular target for cancer therapy.
Discovery of Kisspeptins and KiSS-1

KiSS-1 gene was discovered in 1996 in many mammalian species including rat, mouse and recently identified in fish species. Kisspeptins are C-terminally amidated peptide products encoded by the KiSS-1 gene which is located in long arm of human chromosome 1q32 having four exons consisting of 5' and 3' exons. In humans, this ligand derives from precursor peptide of 145 amino acids in length, with a putative 19 amino acids signal sequence, two potential dibasic cleavage sites, and one putative site for terminal cleavage and amidation. The precursor generates different peptides by photolytic cleavage; thus KPs (also called metastin), is the major peptide that are found to be unstable and may be proteolytically cleaved into the shorter products such as KP-10, KP-13, KP-14 and KP-54 (Smith et al., 2006; Makri et al., 2008).

In this review, these peptides will be collectively referred as Kisspeptins (KPs). Human KiSS-1 gene contains a Phe residue the C-terminal amidated amino acid, while rodents KiSS-1 possess a Tyr residue. The human KP-10 peptide contains Tyr at position one, Trp at position three and Ser at position five. Kisspeptin is a ligand for G-protein coupled receptor (GPR54). All KPs binds to the G-protein coupled receptor (GPCR) and GPR54 exhibits modest sequence identity (34-35%) with the galanin receptors GalR1 and GalR2, but is not activated by galanin. The KiSS-1 gene belongs to a larger family of RFamide (Arg-Phe-NH2) peptide ligand that can activate the human ortholog (hOT7T175 or AXOR12) of GPR54, also termed as KiSS-1 gene plays a major role in regulation of hypothalamic pituitary gonadal (HPG) axis via regulating the secretion of gonadotropin releasing hormone (GnRH) in the hypothalamus. The greatest peripheral source of KPs in the human is placenta and KiSS-1 is located within the syncytiotrophoblast cells (Bilban et al., 2004). Studies on functional analysis have demonstrated the fundamental role of KiSS-1 in multiple process include i.e. sexual differentiation of brain, regulation of gonadotropin secretion via gonadotropin-releasing hormone (GnRH) neurons, action on sex steroids, metabolic regulation of fertility, essential for initiation of human puberty and also maintenance of adult reproduction (Roa and Tena, 2007; 2008; Oakley et al., 2009; Pineda et al., 2010; Hameed et al., 2011; Tena-Sempere et al., 2012). These divulge of KiSS-1 gene and KPs regulate a wider range of effects in the body and interestingly its role in the suppression of metastasis in a variety of cancers appears to be the most important site of action (Makri et al., 2008; Li et al., 2012).

KiSS-1 in Cancer Progression

The expression profile and the role of KiSS-1 gene in cancer progression are largely unknown in most of the cancers (Dhar et al., 2004). GPR54 activation by KPs stimulates phosphatidylinositol 4,5-bisphosphate hydrolysis, calcium mobilization, arachidonic acid release, and ERK1/2 MAPK phosphorylation and has been shown to inhibit cell motility, invasion, proliferation and metastasis (Babwah et al., 2012). However, the precise mechanism of association in tumor metastasis of KPs and GPR54 is still unclear. KiSS-1 became the strongest independent prognostic factor among the conventional prognosticators for gastric cancer patients (Dhar et al., 2004). Hata et al. (2007) reported that low level of KiSS-1 gene expression was associated with more aggressive ovarian cancer cell invasion and also increased in patient’s prognosis. Martin, (2005) reported that over expression of KiSS-1 gene increased the tumor progression during breast cancer. The role of KiSS-1 gene in tumor progression was correlated with over expression of KiSS-1 and GPR54 genes which are found to observed at all advance stages of tumor progression during hepatocellular carcinoma (Ikeguchi et al., 2003; Shengbing et al., 2009). The expression of KiSS-1 was higher in pancreatic cancer results in higher cancer invasion suggesting KiSS can be possible inhibitor of pancreatic cancer invasion (Liang et al., 2007). Dhar et al. (2004) first reported that down regulation of KiSS-1 expression produced frequent tumor invasion and it became a strong prognostic determinant in gastric carcinoma patients. Although KiSS-1 expression level was lower in gastric cancers when compared with normal gastric mucosa, there was a trend of statistical significance between the groups. The author further reveals that this may be due to frequent metaplastic changes in gastric mucosa adjacent to the tumors and might have affected the KiSS-1 gene expression in gastric mucosa.

Homzygous deletion, promoter methylation, or mutation of KiSS-1 gene might be responsible for down regulation of this gene in tumor, responsible for increase in tumor invasion. Similar results were also reported earlier by Sanchez-Carbayo et al. (2003), where low expression of KiSS-1 gene exhibited frequent vascular invasion observed in urinary bladder carcinoma. Therefore KiSS-1 gene expression became an important evocator of cancer patient survival in terms of overall and disease-free survival. Stafford et al. (2002) reported that peptide inhibits cellular proliferation through intracellular Ca++ release and activation of protein kinase C. An increase in intracellular Ca++ was found to inhibit cell proliferation and induce cell differentiation and apoptosis in cancer cells. Therefore evidence claims that KiSS-1 gene continues to be the strongest independent evocator for cancer patient survival. A probable survival supremacy for KiSS-1 gene expression could be attributable to its tumor suppressor role through the prevention of cellular invasion, metastasis and tumor recurrence. Also KiSS-1 has an anti-proliferative effect on cancer cells and could be responsible for decreased tumor growth and increased in cancer patient survival (Dhar et al., 2004). However, more studies are necessary to determine the emergent pathway behind the KiSS-1 gene against all cancers which will shed a new era of cancer treatment by inhibiting the cancer cell invasion.

KiSS-1, as a Molecular Target for Cancer

KiSS-1 gene was identified as a novel human metastatic suppressor gene after the microcell mediated transfer
of intact copy of whole human chromosome 6 into the metastatic human melanoma cell line C8161 without affecting tumourigenicity (Ohtaki et al., 2001; Lee et al., 1996). KiSS-1 gene encodes a carboxyterminal amidated peptide with 54 amino-acid residues which has G-protein-coupled receptor (GPR54, AXOR12 and hOTT1175) also named as metastin. The characterization of the major product of the KiSS-1 gene amino acid peptide ‘metastin’ by virtue of its therapeutic modality that inhibit metastasis of melanoma cells (Funes et al., 2003; Takeda et al., 2012). KiSS-1 gene expression are found in many metastatic melanoma cell lines such as A375SM, WM2664, WM239A, MeWo and strong signals in normal melanocyte FM1085 which blocks the ability of cancer cells to colonize secondary sites by maintaining disseminated tumor cells in a dormant state after they have lodged within the secondary site (Li et al., 2009; Thilolloy et al., 2011). KiSS-1 genes are differential in expression and inversely correlated with metastatic potential of melanoma (Takeda et al., 2012).

Recently, a significant reduction in KiSS-1 or metastin expression has been reported in tumor with high metastatic potential (Sanchez-Carbayo et al., 2003; Dhar et al., 2004; Ikeyuchi et al., 2004; Li et al., 2012). The loss or decreased expression of KiSS-1 gene results in high metastatic potential during cancer progression (Goldberg et al., 2003). Interestingly it was also found that, the Thioredoxin (mapped in chromosome 1) is a class of small redox proteins plays a role in redox signaling that inhibit metastasis of melanoma cells (Funes et al., 2003; Takeda et al., 2012). KiSS-1 gene expression are increased in human breast cancer that supports metastasis. Interestingly, Kostadima, (2007) demonstrated the role of KiSS-1 gene amino acid peptide with 54 amino-acid residues which has G-protein-coupled receptor (GPR54, AXOR12 and hOTT1175) also named as metastin. The characterization of the major product of the KiSS-1 gene amino acid peptide ‘metastin’ by virtue of its therapeutic modality that inhibit metastasis of melanoma cells (Funes et al., 2003; Takeda et al., 2012). KiSS-1 gene expression are found in many metastatic melanoma cell lines such as A375SM, WM2664, WM239A, MeWo and strong signals in normal melanocyte FM1085 which blocks the ability of cancer cells to colonize secondary sites by maintaining disseminated tumor cells in a dormant state after they have lodged within the secondary site (Li et al., 2009; Thilolloy et al., 2011). KiSS-1 genes are differential in expression and inversely correlated with metastatic potential of melanoma (Takeda et al., 2012).

Overall, studies about expression profile of KiSS-1 gene revealed that over-expression of KiSS-1 and its receptor is correlated with disease progression and KiSS-1 gene may be a possible metastasis suppressor of cancers such as thyroid cancer, oesophageal carcinoma, urinary bladder cancer, gastric carcinoma, epithelial ovarian cancer and colorectal cancer (Shirasaki et al., 2001; Ringel et al., 2002; Sanchez-Carbayo et al., 2003; Dhar et al., 2004; Ikeyuchi et al., 2004; Moya et al., 2013). Therefore, numerous experimental and clinical evidences have accumulated unambiguously; support-KiSS-1 could be a potential molecular target for the prognostication and treatment of metastasis during cancer progression. Even though, Kisspeptin and GPR-54 system has been positively correlated with increased patient survival in many cancers, but contradictorily, studies reported that KiSS-1 gene expression were increased in human breast cancer, particularly in patients with aggressive tumor. The author further reports that KiSS-1 gene promotes metastasis in a human breast cancer cell line in an in vitro study (Martin et al., 2005; Makri et al., 2008). In

Kisspeptins (KiSS-1) as Supressors of Cancer Metastasis

(Dhar et al., 2004). Yu, (2007) have studied the protein expression of non-metastatic genes of KiSS-1, KAI-1, nm23 and p53 in gastric tumors with and without lymph node and liver metastases. The author reported that KiSS-1, KAI1 and nm23 levels were drastically reduced in the metastatic tumors compared to tumor at primary site.

Shengbing et al. (2009) demonstrated the role of KiSS-1 gene in tumor invasion as well as in intra-hepatic metastasis and distance metastasis by down regulation of KiSS-1. The authors propose that KiSS-1 gene expression could be a useful prognostic marker in hepatocellular carcinomas (HCC) patients to diagnose the early onset of metastasis and design appropriate therapeutic strategies. Sanchez-Carbayo, (2003) investigated the association between KiSS-1 expression and the clinic pathologic characteristics of bladder tumors and reported that low KiSS-1 gene expression was significantly associated with worse overall survival in 69 bladder cancer patients. The expression of KiSS-1 gene was drastically lower in bladder tumors with vascular invasion compared with normal urothelium. Also the author further reports that all bladder tumors have advanced distant metastases during the loss of KiSS-1. Similarly decreased KiSS-1 gene expression were also confirmed by Takeda et al. (2012) in an separate experiment where they found that, KiSS-1 gene expression in patients with hematogeneous metastases was significantly lower than in those with lymph node metastases. Interestingly, Kostadima, (2007) demonstrated silencing of KiSS-1 gene in patients with high-risk of early breast cancer that supports KiSS-1 gene as metastasis-suppressor gene. The author further reported that KiSS-1 transcriptional activity in patients with node-negative breast cancer, breast cancer primaries and metastatic deposits as well as in patients with other solid tumors was essential. As molecular alteration occur initially in tumors at localized stages. Therefore restoration of KiSS-1 gene function holds promise for arresting micrometastatic growth and preventing cancer recurrence. KiSS-1 gene expression level reportedly to be increased in cancerous tissues as compared to benign tumor (Gao et al., 2007).
support, it is also reported that in hepatocellular cancer Kisspeptin and GPR-54 system have been correlated with decreased survival (Schmid et al., 2007). Even though, Kisspeptins are not always associated positively with some cancers, currently a large body of evidence suggests that, it does appear to inhibit the cancer cell invasion. Different mechanisms of function include increase in ERK1/2 phosphorylation, decrease in MMP-2 as in the placenta as well as to inhibit the metastatic properties of its chemokine receptor CXCR4 have been hypothesised for this inhibition of metastasis process (Statthatos et al., 2005; Yoshioka et al., 2008). These findings may open the possibility of future clinical application of these proteins, KiSS-1 for prevention of cancer invasion and metastasis, and thus may improve patient prognosis. Collectively, this information provoked us to evaluate the expression profile of these genes and their prognostic impact on cancer metastasis, which is the most common cause of cancer death worldwide. Nash and Welch, (2006) reported that KiSS-1 gene expression does not affect initial seeding of metastatic cells to the lung, but prevents tumor cell proliferation after arrival. Although there are some questions which still remain unclear, how KiSS-1 gene maintains dormancy of disseminated cells at the secondary site? In addition, whether KiSS-1 gene will show efficacy in treating larger established metastatic lesions?. However, additional research is needed to demarcate the signalling pathways further and to find an association with cancer prognosis. Cancers associated with KiSS-1 gene and as essential target is presented in (Table 1).

**KiSS-1**

Alternative therapeutic option involves treatment with KPs is feasible because they are secreted. Moreover, systemic administration of KPs could access tumor cells throughout the body. The author reported that metastases to all sites were inhibited by KiSS-1 gene expression and the utilization of KPs block metastases to all tissues (Beck and Welch, 2010). In therapeutic form the author further reveals that, the safety of KiSS-1/KP administration is already proven in humans. Subcutaneous administration of KP54 did not cause any reportable adverse effects but administration of KP54 may regulate endocrine function and the onset of puberty, with activation of the KP receptor triggering the release of gonadotropin releasing hormone (GnRH) (Dhillo et al., 2005a; 2007b). Beck and Welch, (2010) reported that KiSS-1 gene based treatments would be theoretically straightforward as long as the metastatic tumor cells express the KiSS-1 receptor but most of the tumor cells does not express KiSS-1 receptor therefore this could be a challenge for the researcher to develop a multiple cancer treatment with KiSS-1 gene.

**Conclusion**

Collectively, in this review, there exist strong records to substantiated the molecular and functional features of KiSS-1 expression system in a variety of cancer models and these studies suggest that KiSS-1/GPR54 system may participate in fundamental role of tumor biology and metastatic process; therefore, targeting KiSS-1/GPR54 system may represent a novel therapeutic agents for the treatment of metastatic cancer patients. Further investigation is essential to elucidate the complex pathways regulated by the Kisspeptins and how these pathways integrate in the suppression of metastasis across a range of cancers.

**Acknowledgements**

The valuable suggestions from Dr.M.Patrick Gomez, Director, School of Biotechnology and Health Sciences and Dr. Jannet Vennila, Head, Department of Biotechnology, Karunya University, are gratefully acknowledged.

**References**


Beck BH, Welch DR (2010). The KiSS-1 metastasis suppressor:

---

**Table 1. KiSS-1: as an Essential Target in Treatment of Cancer Diseases**

<table>
<thead>
<tr>
<th>Sl No</th>
<th>Types of cancer</th>
<th>Experimental and Clinical evidences</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Skin cancer</td>
<td>Drop in KiSS-1 gene expression coincides with the rapid drop in 5-year survival of patients with tumors &gt;4mm size.</td>
<td>Shirasaki et al., 2001</td>
</tr>
<tr>
<td>2</td>
<td>Thyroid cancer</td>
<td>In well-differentiated thyroid malignancies, papillary carcinomas were more likely to express KiSS-1 mRNA than follicular carcinoma, (69% vs. 20%, p&lt;0.05).</td>
<td>Ringel et al., 2002</td>
</tr>
<tr>
<td>3</td>
<td>Bladder cancer</td>
<td>KiSS-1 mRNA expression was elevated in a cohort of superficial and invasive bladder neoplasms.</td>
<td>Sanchez et al., 2005</td>
</tr>
<tr>
<td>4</td>
<td>Esophageal squamous cell carcinoma</td>
<td>KiSS-1 mRNA expression was evaluated in esophageal squamous cell carcinoma (ESCC). KiSS-1 expression was lost in 38% of ESCC tumors.</td>
<td>Ikeguchi et al., 2004</td>
</tr>
<tr>
<td>5</td>
<td>Gastric cancer</td>
<td>Gastric cancers with low KiSS-1 mRNA had frequent venous invasion, distant metastases, tumor recurrence and a significantly worse overall and disease-free survival has been observed.</td>
<td>Dhar et al., 2004</td>
</tr>
<tr>
<td>6</td>
<td>Hepatocellular carcinoma</td>
<td>KiSS-1 mRNA expression was evaluated in HCC. Ikeguchi et al.,(2004) did not find any significant changes in KiSS-1 gene expression between normal liver and HCC samples, but the lack of correlation with disease cannot be determined because the authors did not include the stage of the clinical specimens examined nor did they report on liver metastases.</td>
<td>Ikeguchi et al., 2004</td>
</tr>
<tr>
<td>7</td>
<td>Breast cancer</td>
<td>Programming of KiSS-1 gene expression in human breast cancer cell lines decreased metastatic spread in mouse xenograft models. Induction of KiSS-1 gene into a metastatic breast cancer cell line MDA-MB-435 reported &gt;65% suppression of metastases to the lung following orthotopic injection.</td>
<td>Obirch et al., 2010; Lee et al., 1996</td>
</tr>
</tbody>
</table>


